Valion Bio, Inc. (NASDAQ:VBIO) announced on October 21, 2026, the findings from its interim chief executive officer, Dean Zikria, following his first 30 days in the role. The filing details a strategic agenda focused on advancing the company's clinical pipeline, commercializing its manufacturing capabilities, and evaluating external partnerships.
The interim CEO’s review prioritizes three main areas. First, the company aims to advance the development of Entolimod, its lead biologic candidate for Acute Radiation Syndrome (ARS). Entolimod has received approximately $35.6 million in non-dilutive funding from U.S. government agencies and holds FDA Fast Track and Orphan Drug designations for ARS. The company is pursuing multiple development pathways for the asset, including a U.S. Department of War-funded program with the Armed Forces Radiobiology Research Institute (AFRRI) focused on gastrointestinal radiation injury, a collaboration with Shear Kershman Laboratories (SKL) on an oral mucosal formulation, and a clinical trial with Sheba Medical Center for cancer patients receiving high-dose radiation.
Second, Valion plans to advance Entolasta, a next-generation Toll-like receptor 5 agonist, which the company views as a potential therapeutic for oncology supportive care and other indications.
Third, the company is focusing on Velocity Bioworks, a wholly owned contract development and manufacturing organization (CDMO). Valion is actively pursuing new customer relationships for Velocity to generate service revenue and improve facility utilization. Additionally, the company has begun evaluating strategic opportunities for Velocity, which may include partnerships, joint ventures, co-investment arrangements, licensing deals, or a sale, with the goal of maximizing the CDMO's value.
Mr. Zikria, who has served on Valion's Board of Directors for more than seven years, stated that the agenda is designed to translate the company's underlying strengths into measurable development progress and commercial traction.
